DPHIL PROJECTS AVAILABLE
MBChB, MRCP, PhD
University Research Lecturer
- British Heart Foundation Intermediate Clinical Research Fellow
Cell and Molecular Biology
My work focuses on understanding how obesity leads to the development of diabetes and cardiovascular disease. In particular, my research aims to understand how a family of growth factors, known as Wnts regulates adipocyte number (adipose tissue 'expandability') and distribution within the body; two key determinants of susceptibility to obesity-associated cardiometabolic disease. In order to achieve this we employ human genetic and physiological approaches, accompanied by functional studies in human fat depot-specific cellular models. Recently we identified a key Wnt receptor, LRP5, as a novel human fat distribution gene.
Of interest LRP5 is a current drug target for the treatment of osteoporosis illustrating the translational potential of the research. In the longer term we hope to exploit our findings to develop novel therapies for obesity and cardiometabolic diseases.
I am currently a BHF Intermediate Clinical Research Fellow and Honorary Consultant in Endocrinology and Diabetes. Prior to this I competed my PhD at the University of Cambridge before taking up an Academic Clinical Lecturer post at the University of Oxford.
TCF7L2 plays a complex role in human adipose progenitor biology, which might contribute to genetic susceptibility to type 2 diabetes.
VERMA M. et al, (2022), Metabolism: clinical and experimental
Apolipoprotein A-V is a potential target for treating coronary artery disease: evidence from genetic and metabolomic analyses.
Ibi D. et al, (2022), J Lipid Res
Sex hormones, adiposity, and metabolic traits in men and women: a Mendelian Randomisation study.
Loh NY. et al, (2022), Eur J Endocrinol
The associations between body fat distribution and bone mineral density in the Oxford Biobank: a cross sectional study.
Hilton C. et al, (2021), Expert Rev Endocrinol Metab, 1 - 7
Higher thyrotropin leads to unfavorable lipid profile and somewhat higher cardiovascular disease risk: evidence from multi-cohort Mendelian randomization and metabolomic profiling.
van Vliet NA. et al, (2021), BMC Med, 19